600976 Stock Overview
Manufactures and sells medicines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Jianmin Pharmaceutical Group Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥45.89 |
| 52 Week High | CN¥66.80 |
| 52 Week Low | CN¥39.75 |
| Beta | 0.73 |
| 1 Month Change | 8.64% |
| 3 Month Change | 7.27% |
| 1 Year Change | -17.85% |
| 3 Year Change | -2.94% |
| 5 Year Change | 180.16% |
| Change since IPO | 457.26% |
Recent News & Updates
Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Anemic Earnings Might Be Worse Than You Think
Mar 29
Investors Holding Back On Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)
Mar 17Recent updates
Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Anemic Earnings Might Be Worse Than You Think
Mar 29Investors Holding Back On Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)
Mar 17Potential Upside For Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) Not Without Risk
Nov 10If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity
Sep 25Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)
Aug 25The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%
Jul 12We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt
Jun 30We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease
May 21We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings
Apr 26Shareholder Returns
| 600976 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.8% | -4.5% | -4.3% |
| 1Y | -17.8% | 3.1% | 7.9% |
Return vs Industry: 600976 underperformed the CN Pharmaceuticals industry which returned 3.1% over the past year.
Return vs Market: 600976 underperformed the CN Market which returned 7.9% over the past year.
Price Volatility
| 600976 volatility | |
|---|---|
| 600976 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in CN Market | 10.9% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 600976 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600976's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 2,497 | Jun Wang | www.whjm.com |
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells medicines in China. It offers medicines and pediatric drugs under the Jianmin, Longmu, and Yekaitai brand name.
Jianmin Pharmaceutical Group Co.,Ltd. Fundamentals Summary
| 600976 fundamental statistics | |
|---|---|
| Market cap | CN¥7.25b |
| Earnings (TTM) | CN¥362.18m |
| Revenue (TTM) | CN¥3.50b |
19.4x
P/E Ratio2.0x
P/S RatioIs 600976 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600976 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.50b |
| Cost of Revenue | CN¥1.83b |
| Gross Profit | CN¥1.67b |
| Other Expenses | CN¥1.31b |
| Earnings | CN¥362.18m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 19, 2025
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 47.73% |
| Net Profit Margin | 10.33% |
| Debt/Equity Ratio | 6.2% |
How did 600976 perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield43%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 09:16 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jianmin Pharmaceutical Group Co.,Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |
| Xiaoyu Qian | Huatai United Securities Co., Ltd. |